XML 38 R26.htm IDEA: XBRL DOCUMENT v3.22.2.2
Note 2 - Summary of Significant Accounting Policies (Details Textual)
6 Months Ended
Jun. 30, 2022
USD ($)
Segment
Dec. 31, 2021
USD ($)
Number of operating segments | Segment 1  
Restricted cash $ 26,000 $ 26,000
Deferred equity issuance costs 263,000,000 0
Accrued clinical trial costs $ 132,000 $ 158,000